drugset / Trial / NCT06509334

Trial of JYB1904 in Chronic Spontaneous Urticaria.

NCT06509334

Phase 2 Recruiting 135 enrolled Jemincare
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

Timeline

Start
2024-08-04
Primary completion
2026-07-15
Completion
2026-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject OZUREPRUBART Monoclonal antibody
Comparator Omalizumab Monoclonal antibody